NVCT Nuvectis Pharma Inc

$NVCT December company will be wrapping up NXP900 1b resistance combo Tagrisso. NVCT my biggest position and believing all 3 drugs will have value in the marketplace. Don't botch this trade, combo can make all other drugs and indications freerolls

$NVCT I'll wait to see if it opens tomorrow around $23 with good volume. Not financial advice :). Info below from my scanner: Buy grade: 6.0 / 10 Confidence: Medium Price (Sep 24, 2026 close): $21.63 Criteria breakdown Longer trend: The stock sits at its 50-day average (~$21.50) and well above its 200-day (~$13) after a climb from the 52-week low of $5.55. It spiked to about $29.27 in late June on the Haisco license news, sold off around the July offering at $20, then traded roughly $20–$25 into September. One-year return is about +250–260%. Valuation: Pre-revenue clinical biotech, so P/E and P/S do not apply. Market cap is about $706–707M. Vendor enterprise value still uses stale June cash ($22M); after the July raise and the $20M Haisco upfront, cash is roughly in the $100M range and EV/cash is closer to about 5.5–6× (estimate from disclosed pieces, not a filed figure). The stock is priced as pipeline optionality, not as an earnings multiple.